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Introduction: Breast cancer cases are increase and fast becoming the leading cause of 
oncologic mortality among women worldwide. Delay in management will worsen the 
prognosis of breast cancer patients. The poor prognosis is correlate with high grade of breast 
cancer malignancy. Histology can be used as an indicator to assess the grade of breast cancer 
malignancy. In addition, a high predictive value of lymphocyte-monocyte ratio (LMR) has 
been suggested to indicate favorable prognosis of various cancer, and used as parameters for 
assessing breast cancer prognosis. 
Aim of study: The purpose of this study is to assess the correlation between lymphocyte-
monocyte ratio and the grade of breast cancer malignancy. 
Method: This study is a quantitative research, using an observational approach. Laboratory 
examination results are collected from 43 breast cancer patients who will conduct treatment at 
Urip Sumoharjo Hospital from June to September 2019. Data are processed by the Spearman 
rank test using SPSS 22.0. 
Results: Correlation test results between lymphocyte-monocyte ratio with histological grading 
of breast cancer obtained a P value of 0.376. 
Conclusions: Lymphocytes to monocytes ratio (LMR) value cannot be utilize as a parameter 
for evaluating prognosis of breast cancer. 




 Cancer is the most common disease in the world for the last decades. Breast cancer is 
the second most common type of cancer after lung cancer. According to data from World 
Health Organizaton (WHO), 2,1 million new cases of breast cancer were diagnosed in 2018. 
One in four women who diagnosed with cancer (24,2%) worldwide is breast cancer.1 The 
incidence rate of breast cancer occupy the most cancer incidence in 25 countries worldwide, 
especially in developing Countries.1,2 There are 4,933 new cases of breast cancer incidence, 
increased from 12.023 cases in 2017 to 16.955 cases in 2018.3,4 Most cases in Indonesia were 
occur in the province of West Java (4,141 cases) followed by Lampung in the fourth place with 
1.836 cases occur in 2018.4 
Breast cancer is one of the five biggest leading causes of death in the world. Data from 
WHO in 2018, shows about 627.000 cases or 6,6% cancer mortality rate are caused by breast 
cancer. Estimated about 15% of total mortality in women are caused by breast cancer, making 
it the most leading cause of death in women.1 In 2018, the mortality rate is estimated at 42.1 
per 100,000 population due to breast cancer in Indonesia and is the highest rate among women.4  
Breast cancer common diagnosed with a relatively good prognosis. The average 5-year 
survival rate for women with breast cancer are around 80-90%. The delayed diagnosis is 
responsible in causing poor prognosis and even mortality of the patient.5 The prognosis of 
breast cancer can be assessed by histopathological gradations according to the Nottingham 
Score which is divided into three grades, grade I (well differentiated),  grade II (moderat 
differentiated), and grade III (poorly differentiated). The higher grade of Nottingham Score is 
associated with poor prognosis.6–8 
However, it is not only the characteristics of the tumor that can determine the prognostic 
of the cancer. The inflammatory response from the host can also be used as a parameter for 
determining the prognosis of cancer.9 Several studies have shown that systemic inflammation 
can stimulate tumor development by inhibiting apoptosis, stimulating angiogenesis and DNA 
damage. Hematologic index for systemic inflammation, such as leukocyte count, monocyte 
count, platelet count, neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR) 
and platelet-lymphocyte ratio (PLR) have been proposed as prognostic factors in cases of lung, 
stomach and breast cancer.10 
 Several studies have shown that LMR is associated with the prognosis of cancer.11 A low 
preoperative lymphocyte-monocyte ratio is associated with a poor prognosis in patients with 
cervical cancer and several other types of cancer.12 Low lymphocyte-monocyte ratio is 
associated with poor life expectancy of patients with breast cancer.9 According to that, this 




Quantitative study with observational approach were used in this study. It was conducted 
from June to September 2019 at three laboratory, which are Clinical Pathology Laboratory of 
Urip Sumoharjo Hospital, Anatomical Pathology Laboratory of Urip Sumoharjo Hospital and 
Anatomy, Histology and Phatology Anatomy Laboratory, Faculty of Medicine, University of 
Lampung. This study used laboratory examination results of breast cancer patients who will 
conduct treatment at Urip Sumoharjo Hospital Bandar Lampung in June - September 2019 as 
the data. This study were using consecutive sampling as sample selection method with 
inclusion criteria as followed; (i) no history of cancer before; (ii) never received chemotherapy 
treatment; and (iii) not taking anti-inflammatory medication before. Based on these inclusive 
criteria, 43 samples were obtained in this study. 
This study began with the collection of breast cancer patients at Urip Sumoharjo Hospital 
during the period of June - September 2019 according to patient's medical record. Samples that 
have fulfilled the criteria are then continue to laboratory examination. There are basic 
hematology parameter test, and histopathological examination of breast biopsy from each 
laboratory. Examination data obtained in the form of hemoglobin, leukocytes, neutrophils, 
lymphocytes, monocytes and platelets count for hematological examination parameters as well 
as the type of histology and grade of breast cancer malignancy on histopathological 
examination. 
The results of this study are numerical data (ratios) for basic hematological test parameters 
and categorical data for breast cancer grading. Data were analyzed with the Spearman rank 
test using the SPSS 22.0 device to evaluate the correlation between lymphocyte-monocyte 
ratio and the grade of malignancy in breast cancer patients. 
  
Results 
Examination has been carried out on 43 breast cancer patients who will undergo 
treatment at Urip Sumahardjo Hospital in June - September 2019 who have met the inclusion 
criteria. Charatacteristic of patients age and ditribution was divided into four groups with the 
highest frequency in the 40-50 group with a total of 25 people (58.14%). The age distribution 
of the study sample is described in table one.  
Data on hematological examination results from 43 samples are described in highest, 
lowest and average values of all samples. Assessment of lymphocyte-monocyte ratio (LMR) is 
determine by dividing the value of the lymphocytes count by monocytes count. The highest, 
lowest and average values of LMR are 10; 0,36; and 3,87 respectively. Characteristics of 
haematology and LMR examination results are described in table two. 
Histopathological examination results of 43 samples were described into two categories, 
there are classification of breast cancer types and the histological grading. Type of breast cancer 
are classified into three categories based on specific cells that are affected. Most frequent type 
is ductal carcinoma invasion, found in 35 samples  (81.39%). While the classification based on 
the histological grading divided into three grades with the most common is grade III, found in 
28 samples (65.12%). Result of Hisopathological examination characteristic are described in 
table three. 
Correlation test result between grading of malignancy and basic haematological test 
parameter (Hb, Leukocytes, and platelet count) are described in table four. Table four shows 
various results for each parameter. Spearman Rank correlation test results between grading of 
malignancy with Hb levels (r = 0.251; p = 0.104) and platelets (r = -0.091; p = 0.562), does not 
show a significant correlation statistically. In line with the previous parameters, grading of 
malignancy does not show a correlation with the number of leukocytes (r = 0.111, p = 0.479), 
with neutrophils (r = 0.100; p = 0.484), with lymphocytes (r = -0.227; p = 0.144), and with 
monocytes (r = -0.017; p = 0.915). 
Spearman Rank test results show LMR values < 2.5 are found in 11 people with grade 
III (25.58%), followed by three people with grade II (6.98%). LMR values range from 2.5 to 
5.0 were found in 11 samples with grade III (25.58%), 6 samples with grade II (13.95%) and 2 
 samples with grade I  (4.65%). While the LMR value > 5.0 were found in six people with grade 
III (13.95%) and four people with grade II (9.3%). The results of the Spearman Rank Test 
between the grading of malignancy and LMR are described in table five. 
 
Table 1. Age Distribution of Samples 
 
Age Frequency Percentage 
< 40 years old 5 11,63 % 
40 - 50 years old 25 58,14 % 
51  - 60 years old 11 25,58 % 
> 60 years old 2 4,65 % 
 
 
Table 2. Characteristics of Hematology and LMR Examination Results 
 
Variables  Min. Max. Mean±SD 
Hemoglobin (g/dL) 7,1 15,6 11,7±1,8 
Lekocyte (Sel/µL) 1.250 16.060 7760,69±2971 
Neutrophil (%) 32 93 63,58±14,3 
Limphocyte (%) 5 47,7 25,64±13,57 
Monocyte (%) 2 41,8 9,08±0,8 
Platelet 91.000 515.000 276.000±89.583 
LMR 0,36 10 3,87±3,06 
 
 
Table 3. Characteristics of Histopathological Examination Results 
 
Variables Frequency Percentage 
Breast cancer type   
-. Invasif Ductal Carcinoma 35 81,39 % 
-. Invasive Lobular Carcinoma 6 13,95 % 
-. Others 2 4,65 % 
Histological grading   
-. Grade I 2 4,65 % 
-. Grade II 13 30,23 % 















Hemoglobin 0,251 0,104 
Leukocyte  0,111 0,479 
Platelet - 0,091 0,562 
Neutrophil 0,110 0,484 
Limphocyte  -0,227 0,144 




Table 5. Correlation between LMR with Grading of Breast Cancer Malignancy 
Breast Cancer  
LMR 
Grade I Grade II Grade III Total 
p 
n % n % n % n % 
< 2,5   3 6,98 11 25,58 14 32,56  
0,376 2,5 – 5,0 2 4,65 6 13,95 11 25,58 19 44,19 
>5,0   4 9,3 6 13,95 10 23,26 
 
Discussion 
Recent studies shows that systemic inflammation is correlated with cancer. Inflammation 
impacts each step of tumorgenesis, including tumor initiation, promotion and metastatic 
progression. Inflammatory indicators that can be used as biomarkers in cancer prognostics are 
neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and lymphocyte-monocyte ratio.9,13 
Systemic inflammatory biomarkers are hypothesized reresenting circulating cells, specifically 
the lymphocytes to monocytes ratio (LMR),  LMR value have been reported to be prognostic 
factors in breast cancer. Accumulated evidence shows that infiltration inflammatory cells in 
the tumor microenvironment have a significant effect on tumor initiation, proliferation, 
angiogenesis and metastasis.14 
Lymphocytes have a major role in suppressing proliferation, migration of cancer cells, 
and cell death. Tumor Infiltrating Lymphocytes (TIL) is a vital component of the antitumor 
immunity microenvironment and is involved in several stages of tumor development. Cytotoxic 
lymphocytes and cytotoxic T cells play an important role in removing residual cancer cells. 
Therefore, a decrease in the value of lymphocytes affecting immunological reactions to tumors, 
thereby increasing tumor growth and metastasis.9,15 
 Monocytes are known to have an effect on tumor growth. Monocytes can infiltrate tumors 
and will differentiate into Tumor Associated Macrophages (TAMs). It is known that TAM is 
involved in proliferation, invasion, metastasis, tumor neovascularization and recurrence. 
Therefore, the number of monocytes can represent the number of TAMs. Increased monocyte 
count represent a high tumor burden in patients with cancer.9,15 
According to mechanism of lymphocytes and monocytes, LMR is believed to reflect the 
host's immune status and tumor development level. Low lymphocyte with high monocyte 
counts represent inadequate anti-tumor immunity and increased tumor burden. A low LMR 
predictive value associated with a worse cancer prognosis. LMR value represent the balance 
between benefits of lymphocytes role with the lack of monocytes role in the process of cancer 
Development.9 Lymphocytes to monocytes ratio (LMR) values have also been found to be 
associated with survival rates of malignant lymphoma patients and various solid tumors, 
including breast cancer.16 
Many studies have shown that LMR values are reported to be prognostic factor of several 
cancer, including breast cancer. He, et al reported the LMR value can be used as a predictive 
factor in long-term survival of triple negative breast cancer patients.17 In line with these 
findings, Curcio et al found that LMR can be used as a marker in breast cancer, especially in 
triple negative types of breast cancer and luminal B-like breast cancer.18 In addition, Hu et al 
reported that low LMR values associated with poor prognosis in breast cancer.19 High LMR 
values suggesting a good prognosis in breast cancer patients with luminal subtypes treated with 
5-flourouracil chemotherapy.13  
Other studies assessing the prognostic function of B cells infiltrating tumors, especially 
in breast cancer, report positive or negative prognostic values. Recent meta-analysis reported 
an increase in CD20+ B cell counts associated with disease free survival (DFS) and breast 
cancer specific survival (BCSS).20 In contrast with that, CD19+ B cell counts have a poor 
prognostic value in breast cancer patient that has been assess with indicators such as estrogen 
/ progesterone receptors, metastasis to lymph nodes, tumor histology Grande III, and T4 status 
against TNM.21 In addition, some studies reports that there is a weak correlation between CD20 
+ cells with histological features, Cycling A or Ki67 in breast cancer.22 
 Several previous studies illustrate the correlation results in certain breast cancer subtypes 
showing that each subtypes has heterogeneous antitumor cells. Thus, each of these cancer 
subtypes will induce a different host response. Thereby, the value or level of each 
immunological cell produced by each subtype has a different number and the.13,15 
In addition, the cut-off determination of LMR values in several studies are using various 
reference. Therefore, there is no standard reference in determining categories in LMR values.13 
Overall, the prognostic assessment of breast cancer using lymphocytes or B cells shows various 
results depends on the condition of the disease. furthermore, the determination of LMR value 
cut-off point must be adjusted to the type or subtype of cancer, thereby different immune 
responses and other biases can be eliminated.13,15 
 
Conclusion 
Lymphocytes to monocytes ratio (LMR) value cannot be utilize as a parameter for 
evaluating prognosis of breast cancer. 
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